睿知中国疾病研究地图
候选清单0

邀请入组胃癌早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Clinical Efficacy of Pucotenlimab Combined With Lenvatinib and SOX Versus SOX Alone in Patients With HER2-Negative Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov 上登记的一项胃癌开放试验,由福建医科大学附属协和医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)福建医科大学附属协和医院Fujian Medical University Union Hospital福州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07356466,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 5

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(5 项)收起清单
  1. 18 岁 至 75 岁;性别:不限

    登记记录的入选字段

  2. No prior systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy for advanced disease. Subjects who have received prior (neo)adjuvant chemotherapy and/or radiotherapy are eligible provided the last dose was completed ≥ 6 months before randomisation.

    入选标准第 1 条

    Serum creatinine ≤ 1 × ULN and calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula) 8. Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrolment and must use highly effective contraception from screening until 8 weeks after the last dose of study drug. Men must be surgically sterile or agree to use effective contraception during the same period.

    入选标准第 12 条

    Prior exposure to: anti-PD-1, anti-PD-L1, anti-PD-L2, or any agent targeting other T-cell co-stimulatory or co-inhibitory pathways (including but not limited to CTLA-4, OX-40, CD137); or prior chemotherapy including S-1.

    排除标准第 5 条

  3. At least one measurable lesion per RECIST 1.1 (see Appendix 2). 5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 (see Appendix 4).

    入选标准第 2 条

  4. WBC ≥ 3 × 10⁹/L

    入选标准第 6 条

    ANC ≥ 1.5 × 10⁹/L

    入选标准第 7 条

    Total bilirubin < 1.5 × upper limit of normal (ULN)

    入选标准第 10 条

    ALT and AST < 2.5 × ULN; ALP ≤ 1.5 × ULN

    入选标准第 11 条

  5. Other malignancies within the past 5 years, except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix.

    排除标准第 2 条

    Currently receiving treatment in another interventional clinical trial, or any systemic anti-gastric-cancer therapy within 4 weeks prior to the first dose.

    排除标准第 3 条

    Chronic hepatitis B with active replication (HBV DNA > 1 × 10⁴ copies/mL or > 2000 IU/mL);

    排除标准第 22 条

    Hepatitis C with detectable HCV RNA (> 1 × 10³ copies/mL);

    排除标准第 23 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:诊断及确认方式;分期或严重程度(按试验的定义);影像与可测量病灶;怀孕、哺乳与避孕。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07356466,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. No prior systemic chemotherapy, radiotherapy, targeted therapy, or immunotherapy for advanced disease. Subjects who have received prior (neo)adjuvant chemotherapy and/or radiotherapy are eligible provided the last dose was completed ≥ 6 months before randomisation.
  2. At least one measurable lesion per RECIST 1.1 (see Appendix 2). 5. Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 (see Appendix 4).
  3. Estimated life expectancy > 3 months. 7. Adequate major organ function defined as:
  4. Haematology (obtained ≤ 14 days without transfusion):
  5. Hb ≥ 80 g/L
  6. WBC ≥ 3 × 10⁹/L
  7. ANC ≥ 1.5 × 10⁹/L
  8. PLT ≥ 100 × 10⁹/L
  9. Biochemistry:
  10. Total bilirubin < 1.5 × upper limit of normal (ULN)
  11. ALT and AST < 2.5 × ULN; ALP ≤ 1.5 × ULN
  12. Serum creatinine ≤ 1 × ULN and calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula) 8. Women of child-bearing potential must have a negative serum pregnancy test within 7 days prior to enrolment and must use highly effective contraception from screening until 8 weeks after the last dose of study drug. Men must be surgically sterile or agree to use effective contraception during the same period.
  13. No participation in any other interventional clinical trial during the pre-treatment or on-treatment phases of this study.
  14. Voluntary written informed consent obtained; willing and able to comply with study procedures and follow-up.

排除标准:Exclusion Criteria:

  1. Known or suspected hypersensitivity to the investigational drug or any drug of the same class.
  2. Other malignancies within the past 5 years, except adequately treated basal-cell or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix.
  3. Currently receiving treatment in another interventional clinical trial, or any systemic anti-gastric-cancer therapy within 4 weeks prior to the first dose.
  4. Systemic Chinese patent medicines with anti-tumor indications or immunomodulatory agents (e.g., thymosin, interferon, interleukins; local intrapleural use for effusion control is permitted) received within 2 weeks before the first dose.
  5. Prior exposure to: anti-PD-1, anti-PD-L1, anti-PD-L2, or any agent targeting other T-cell co-stimulatory or co-inhibitory pathways (including but not limited to CTLA-4, OX-40, CD137); or prior chemotherapy including S-1.
  6. Live-vaccine administration within 4 weeks before enrollment or planned during the study.
  7. Active autoimmune disease requiring systemic therapy (e.g., immunosuppressants, corticosteroids, or disease-modifying agents) within 2 years before the first dose. Replacement therapy (thyroxine, insulin, physiologic glucocorticoids for adrenal or pituitary insufficiency) is not considered systemic therapy.
  8. Prior allogeneic bone-marrow or solid-organ transplantation.
  9. Any condition that could impair drug absorption or inability to swallow oral medication.
  10. Uncontrolled hypertension despite optimal medical management:
  11. SBP ≥ 150 mmHg or DBP ≥ 100 mmHg on a single antihypertensive, or requirement of ≥ 2 antihypertensive agents.
  12. Urinalysis showing proteinuria ≥ 2+ and 24-h urinary protein > 1.0 g.
  13. Active gastro-duodenal ulcer, ulcerative colitis, or other gastrointestinal disorders with bleeding risk; un-resected tumors with active hemorrhage; or any other condition judged by the investigator to predispose to GI bleeding or perforation.
  14. Significant bleeding tendency within 3 months before enrollment: overt bleeding > 30 mL, hematemesis, melena, hematochezia; hemoptysis (> 5 mL fresh blood within 4 weeks); or thrombo-embolic event (including stroke/TIA) within 12 months.
  15. Clinically significant cardiovascular disease:
  16. Acute MI, unstable/severe angina, or CABG within 6 months before enrollment;
  17. NYHA class > II congestive heart failure;
  18. Ventricular arrhythmia requiring therapy;
  19. QTc ≥ 480 ms on baseline ECG.
  20. Active or uncontrolled severe infection (≥ CTCAE grade 2).
  21. Known HIV infection; clinically significant hepatic disorders:
  22. Chronic hepatitis B with active replication (HBV DNA > 1 × 10⁴ copies/mL or > 2000 IU/mL);
  23. Hepatitis C with detectable HCV RNA (> 1 × 10³ copies/mL);
  24. Other hepatitis or cirrhosis.
  25. Known dihydropyrimidine dehydrogenase (DPD) deficiency.
  26. Any condition that, in the opinion of the investigator, would compromise the subject's safety or interfere with study participation.

引自 ClinicalTrials.gov, NCT07356466, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07356466,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07356466